KPI data tables

Emergent BioSolutions operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

Emergent MCM Product Sales USG vs Non-USG (Annual) (usd_millions)
PeriodUSG MCMNon-USG MCM
FY 2025300.2156.5
FY 2024381.3128.5
FY 2023373.573.7

Source: Emergent Form 10-K for the year ended December 31, 2025, Note 14 Revenue recognition, MCM Product sales USG / Non-USG / Total (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm): FY 2025 $300.2 / $156.5 / $456.7 million. FY 2024 $381.3 / $128.5 / $509.8 million. FY 2023 $373.5 / $73.7 / $447.2 million. FY 2025 international MCM share of 34% of MCM revenue: Q4 2025 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000012/ebs2025-12x31deck.htm). H1 2026 international MCM 20% of H1 MCM revenues: Q2 2026 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000080/ebs2026-06x30deckfinal.htm).

Emergent NARCAN Nasal Spray Doses Distributed (Annual) (million_doses)
PeriodNARCAN doses (millions)
FY 202422
FY 202322

Source: Emergent Q4 2023 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764424000026/ebs2023-12x31deckfinalmi.htm): in 2023, distributed about 22 million doses / about 11 million two-dose boxes in the US and Canada. Q4 2024 earnings presentation (https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs2024-12x31deck.htm): in 2024, distributed about 11 million cartons / 22 million doses, consistent with 2023. FY 2025 annual report letter (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000035/ebsi_2025annualreport.htm): distributed over 100 million doses of NARCAN Nasal Spray across the US and Canada since 2016 (cumulative floor, not an annual print).

Emergent Product Sales by Franchise (Quarterly) (usd_millions)
PeriodNaloxone (NARCAN / KLOXXADO)Anthrax MCMSmallpox MCMOther Products (BAT / RSDL)
Q3 202643.525.126.77.6
Q2 202652.412.3101.654.1
Q1 202642.921.664.216
Q4 202538.453.435.510.3
Q3 202574.91.483.657.5
Q2 202567.511.640.66.2
Q1 202545.347.9106.42.3
Q4 202465.132.576.57.8
Q3 202495.311.4132.730.1
Q2 202412038.717.96.8
Q1 2024118.555.950.249.3

Source: Emergent BioSolutions product sales, net tables in quarterly earnings releases and Form 10-Q/10-K MD&A. Q1 2024: https://www.globenewswire.com/news-release/2024/05/01/2873704/33240/en/Emergent-BioSolutions-Reports-First-Quarter-2024-Financial-Results.html (NARCAN 118.5, Anthrax 55.9, Smallpox 50.2, Other 49.3). Q2 2024: https://investors.emergentbiosolutions.com/node/23031/pdf (120.0 / 38.7 / 17.9 / 6.8). Q3 2025 release reprints Q3 2024: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000198/ebs2025-09x30ex99er.htm (95.3 / 11.4 / 132.7 / 30.1). Q4 2025 release reprints Q4 2024: https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-reports-fourth-quarter-and-full-year-2025 (65.1 / 32.5 / 76.5 / 7.8). FY 2025 10-K annuals (226.1 / 114.3 / 266.1 / 76.3) at https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm. Q1 to Q4 2025 from the Q4 2025, Q3 2025, and Q2 2026 comparisons. Q1 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs20260331ex99er.htm (42.9 / 21.6 / 64.2 / 16.0). Q2 2026 Form 10-Q: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/ebs-20260630.htm (52.4 / 12.3 / 101.6 / 54.1). Q3 2026 Form 8-K Exhibit 99.1: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000110/ebs202609-30ex99er.htm (43.5 / 25.1 / 26.7 / 7.6).

Emergent Remaining Performance Obligations (Quarterly) (usd_millions)
PeriodTotal RPOExpected within 24 months
Q3 2026241.9222.7
Q2 2026268.7247.7
Q1 2026248210.4
Q4 2025244.4203.8
Q3 2025322.5259.2
Q2 2025296.9227.5
Q1 2025270.4199.3
Q4 2024393.2348.2

Source: Emergent Form 10-K and Form 10-Q, Revenue recognition note, Transaction price allocated to remaining performance obligations. YE 2024: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000021/ebs-20241231.htm ($393.2 million total, $348.2 million within 24 months). Q1 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000124/ebs-20250331.htm ($270.4 / $199.3). Q2 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000181/ebs-20250630.htm ($296.9 / $227.5). Q3 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000202/ebs-20250930.htm ($322.5 / $259.2). YE 2025: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm ($244.4 / $203.8). Q1 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000065/ebs-20260331.htm ($248.0 / $210.4). Q2 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000082/ebs-20260630.htm ($268.7 / $247.7). Q3 2026: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000112/ebs-20260930.htm ($241.9 / $222.7).

Emergent US Government vs Non-USG Revenue (Annual) (usd_millions)
PeriodUS governmentNon-USG customers
FY 2025339.7403.2
FY 2024410.5633.1
FY 2023394.7654.6

Source: Emergent Form 10-K for the year ended December 31, 2025, Note 14 Revenue recognition, revenues disaggregated by major sources (https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm). FY 2025: USG $339.7 million, Non-USG $403.2 million, total $742.9 million. FY 2024: $410.5 / $633.1 / $1,043.6 million. FY 2023: $394.7 / $654.6 / $1,049.3 million. Same note: no non-USG customer above 10% of total revenues in those years. US geographic share 71% / 79% / 58% for 2025 / 2024 / 2023 is printed separately and is not this series.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Emergent BioSolutions (EBS) - KPIs | Sterling